Anti-Human CD194 (CCR4) (Mogamulizumab) – Biotin
Anti-Human CD194 (CCR4) (Mogamulizumab) – Biotin
Product No.: LT1001
- -
- -
Product No.LT1001 Clone KW-0761 Target CD194 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names Mogamulizumab, CD194, CCR4 Isotype Human IgG1κ Applications Depletion , ELISA , FA , FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Humanization of mouse anti-CCR4 mAb7. Product Concentration 0.5 mg/ml Formulation This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893875 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Mogamulizumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. ELISA Additional Applications Reported In Literature ? FA Additional Reported Applications For Relevant Conjugates ? Depletion Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Mogamulizumab. Clone KW-0761 recognizes human CD194 (CCR4). This product is for research use only. Antigen Distribution CCR4 is primarily expressed by Th2 and regulatory T cells in addition to expression on leukemic cells in cutaneous T-cell lymphoma (CTCL). Background Clone KW-0761 (Mogamulizumab) is a research-grade, afucosylated, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4.1 CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1–infected cells and the levels of inflammatory markers related to HTLV-1–Associated Myelopathy.3 Antigen DetailsPubMed NCBI Gene Bank ID UniProt.org Research Area Cancer . Immuno-Oncology . Immunology References & Citations1. Yamamoto, K. et al. (2010) J Clin Oncol. 28(9):1591-8. 2. Mimura, Y. et al. (2018) Protein Cell 9(1):47-62. 3. Yamano, Y. et al. (2018) N Engl J Med 378 (6), 529-538. Technical ProtocolsDepletion  FA  |
Formats Available
- -
- -
Prod No. | Description |
|---|---|
LT1000 | |
LT1002 | |
LT1001 | |
LT1006 | |
LT1005 | |
LT1007 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
